A Protein Aggregation Inhibitor, Leuco-Methylthioninium Bis(Hydromethanesulfonate), Decreases α-Synuclein Inclusions in a Transgenic Mouse Model of Synucleinopathy

Alpha-Synuclein transgenic mice, h-α-SynL62, display α-Syn aggregation and a dopaminergic phenotype reminiscent of Parkinson’s disease

(2018) Silke Frahm et al.   BEHAVIOURAL BRAIN RESEARCH

A routinely used protein staining dye acts as an inhibitor of wild type and mutant alpha-synuclein aggregation and modulator of neurotoxicity

(2018) Nuzhat Ahsan et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer’s Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial

(2017) Gordon K. Wilcock et al.   JOURNAL OF ALZHEIMERS DISEASE

α-Synuclein aggregation, seeding and inhibition by scyllo-inositol

(2016) Tarek Ibrahim et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Baicalein inhibits α-synuclein oligomer formation and prevents progression of α-synuclein accumulation in a rotenone mouse model of Parkinson's disease

(2016) Qi Hu et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial

(2016) Serge Gauthier et al.   LANCET

Potential Pathways of Abnormal Tau and α-Synuclein Dissemination in Sporadic Alzheimer's and Parkinson's Diseases

(2016) Heiko Braak et al.   Cold Spring Harbor Perspectives in Biology

Fasudil attenuates aggregation of α-synuclein in models of Parkinson’s disease

(2016) Lars Tatenhorst et al.   Acta Neuropathologica Communications

Effects of oxidized and reduced forms of methylthioninium in two transgenic mouse tauopathy models

(2015) Valeria Melis et al.   BEHAVIOURAL PHARMACOLOGY

Cellular Models of Aggregation-dependent Template-directed Proteolysis to Characterize Tau Aggregation Inhibitors for Treatment of Alzheimer Disease

(2015) Charles R. Harrington et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Parkinson Disease Mutant E46K Enhances α-Synuclein Phosphorylation in Mammalian Cell Lines, in Yeast, andin Vivo

(2015) Martial Kamdem Mbefo et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Serotonergic dysfunction in the A53T alpha-synuclein mouse model of Parkinson's disease

(2015) Janina Deusser et al.   JOURNAL OF NEUROCHEMISTRY

Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations

(2015) Benjamin Dehay et al.   LANCET NEUROLOGY

Binding interactions of agents that alter α-synuclein aggregation

(2015) K. Sivanesam et al.   RSC Advances

Next-generation active immunization approach for synucleinopathies: implications for Parkinson’s disease clinical trials

(2014) Markus Mandler et al.   ACTA NEUROPATHOLOGICA

Different pathways of molecular pathophysiology underlie cognitive and motor tauopathy phenotypes in transgenic models for Alzheimer’s disease and frontotemporal lobar degeneration

(2014) V. Melis et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Immunotherapy targeting α-synuclein protofibrils reduced pathology in (Thy-1)-h[A30P] α-synuclein mice

(2014) Veronica Lindström et al.   NEUROBIOLOGY OF DISEASE

Immunolocalization of human alpha-synuclein in the Thy1-aSyn (“Line 61”) transgenic mouse line

(2014) M. Delenclos et al.   NEUROSCIENCE

α-Synuclein Immunotherapy Blocks Uptake and Templated Propagation of Misfolded α-Synuclein and Neurodegeneration

(2014) Hien T. Tran et al.   Cell Reports

Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson’s disease

(2013) Jens Wagner et al.   ACTA NEUROPATHOLOGICA

Methylthioninium chloride (methylene blue) induces autophagy and attenuates tauopathy in vitro and in vivo

(2012) Erin E. Congdon et al.   Autophagy

Cognitive deficits in a mouse model of pre-manifest Parkinson’s disease

(2012) Iddo Magen et al.   EUROPEAN JOURNAL OF NEUROSCIENCE

Antibody-Aided Clearance of Extracellular  -Synuclein Prevents Cell-to-Cell Aggregate Transmission

(2012) E.-J. Bae et al.   JOURNAL OF NEUROSCIENCE

Exosomal cell-to-cell transmission of alpha synuclein oligomers

(2012) Karin M Danzer et al.   Molecular Neurodegeneration

The many faces of α-synuclein: from structure and toxicity to therapeutic target

(2012) Hilal A. Lashuel et al.   NATURE REVIEWS NEUROSCIENCE

Comparison of motor performance, brain biochemistry and histology of two A30P α-synuclein transgenic mouse strains

(2012) M. Piltonen et al.   NEUROSCIENCE

Pathological  -Synuclein Transmission Initiates Parkinson-like Neurodegeneration in Nontransgenic Mice

(2012) K. C. Luk et al.   SCIENCE

Enhancement of proteasome activity by a small-molecule inhibitor of USP14

(2010) Byung-Hoon Lee et al.   NATURE

Cell-to-cell transmission of non-prion protein aggregates

(2010) Seung-Jae Lee et al.   Nature Reviews Neurology

Inclusion formation and neuronal cell death through neuron-to-neuron transmission of  -synuclein

(2009) P. Desplats et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Disease-modifying drugs and Parkinson's disease

(2007) Hervé Allain et al.   PROGRESS IN NEUROBIOLOGY